Serial dilutions create a range of virus concentrations, allowing researchers to identify a dilution that produces countable plaques, infected cell foci, or cytopathic effects. Comparing responses across dilutions supports calculation of infectious units rather than relying on a single potentially overcrowded or indistinct measurement. The dilution series also makes samples with different starting concentrations more comparable.
These readouts provide observable evidence that infectious virus affected susceptible cultured cells. Plaques and infected foci can be quantified directly, while cytopathic effects provide a measurable cellular response used in the assay. Selecting a suitable readout determines how infectious virus is quantified and whether results are reported as plaque-forming units or another assay-based measure.
Susceptible cells provide the biological system in which virus can produce a measurable effect. Without an appropriate cellular response, the assay cannot distinguish infectious activity through plaques, infected foci, or cytopathic effects. This requirement makes the cell culture component central to interpreting a sample's infectious concentration, rather than simply detecting virus-related material.
PFU and TCID50 are reporting formats linked to different ways of quantifying infectious virus in cultured cells. Plaque-based measurements are commonly expressed as plaque-forming units, whereas TCID50 represents another assay-based infectious measurement. The reported unit therefore communicates how the infectious effect was detected and supports consistent comparison within and across experiments.
A typical workflow begins with preparing serial dilutions of the virus-containing sample. Researchers then expose susceptible cultured cells to those dilutions and monitor the cultures for plaques, infected cell foci, or cytopathic effects. They quantify the selected endpoint and use the dilution results to calculate the infectious concentration, producing a standardized value for later experiments.
Viral titering is useful when experiments require a standardized inoculum or quantitative comparison of infectious virus. It supports studies of viral replication, neutralization, vaccines, antiviral treatments, and host immune responses. Reliable titers help researchers interpret whether differences between conditions reflect altered infection or treatment and immune effects, while improving reproducibility across infection models.